The drug is intended to treat acute bacterial skin and skin structure infections caused by certain susceptible bacteria like Staphylococcus aureus, including methicillin-susceptible and methicillin-resistant strains, and Streptococcus pyogenes. The treatment is administered intravenously.
Dalvance is the first drug designated as a Qualified Infectious Disease Product to receive FDA approval. It was granted QIDP designation because it is an antibacterial or antifungal human drug intended to treat serious or life-threatening infections. As a QIDP, the drug was also given priority review.
More Articles on Quality:
Despite Guidelines, Antibiotics Prescribed at High Rate for Bronchitis
New Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
